Lemtrada

Product manufactured by Genzyme Corporation

Application Nr Approved Date Route Status External Links
BLA103948 None Intravenous None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Lemtrada Is Indicated For The Treatment Of Relapsing Forms Of Multiple Sclerosis (Ms), To Include Relapsing-Remitting Disease And Active Secondary Progressive Disease, In Adults. Because Of Its Safety Profile, The Use Of Lemtrada Should Generally Be Reserved For Patients Who Have Had An Inadequate Response To Two Or More Drugs Indicated For The Treatment Of Ms [See Warnings And Precautions (5) ] . Lemtrada Is A Cd52-Directed Cytolytic Monoclonal Antibody Indicated For The Treatment Of Relapsing Forms Of Multiple Sclerosis (Ms), To Include Relapsing-Remitting Disease And Active Secondary Progressive Disease, In Adults. Because Of Its Safety Profile, The Use Of Lemtrada Should Generally Be Reserved For Patients Who Have Had An Inadequate Response To Two Or More Drugs Indicated For The Treatment Of Ms [See Warnings And Precautions (5) ] . ( 1 ) Limitations Of Use : Lemtrada Is Not Recommended For Use In Patients With Clinically Isolated Syndrome (Cis) Because Of Its Safety Profile [See Warnings And Precautions (5) ] . ( 1 ) Limitations Of Use Lemtrada Is Not Recommended For Use In Patients With Clinically Isolated Syndrome (Cis) Because Of Its Safety Profile [See Warnings And Precautions (5) ].

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Alemtuzumab

Comments